Screener
PTC Therapeutics PTCT Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $833,986 | $984,648 |
| Marketable securities | 1,058,477 | 960,723 |
| Trade and royalty receivables, net | 219,919 | 181,621 |
| Inventory, net | 75,567 | 79,647 |
| Prepaid expenses and other current assets | 66,054 | 67,309 |
| Total current assets | 2,254,003 | 2,273,948 |
| Fixed assets, net | 52,739 | 55,371 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's accounts receivable?
- PTC Therapeutics (PTCT) reported accounts receivable of $219.92M in Q1 2026.
- How has PTC Therapeutics's accounts receivable changed year-over-year?
- PTC Therapeutics's accounts receivable increased by 4.5% year-over-year, from $210.5M to $219.92M.
- What is the long-term trend for PTC Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), PTC Therapeutics's accounts receivable has grown at a 21.0% compound annual growth rate (CAGR), from $69.93M to $181.62M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about PTC Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude